NEU 0.00% $17.09 neuren pharmaceuticals limited

Ann: Q2 2024 update, page-41

  1. 1,673 Posts.
    lightbulb Created with Sketch. 168
    It is also interesting whilst not a material number, they have seen some patients have completely discontinued restart on the treatment. Presumably after the new data has been presented (ie more benefits over time), along with GI management guidelines.

    "On restarts, we're beginning to see some patients begin to come back onto therapy, but our focus has been on ensuring a very positive treatment initiation. It's important for those patients that have been on therapy for the long term "
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.